# Dapagliflozin + Saxagliptin in a Basal-bolus Insulin Treatment

> **NCT02965443** · PHASE4 · TERMINATED · sponsor: **University Hospital Tuebingen** · enrollment: 4 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Dapagliflozin 10 mg + Saxagliptin 5 mg
- **DRUG:** Placebo 1 10 mg + Placebo 2 5 mg

## Key facts

- **NCT ID:** NCT02965443
- **Lead sponsor:** University Hospital Tuebingen
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-02-02
- **Primary completion:** 2020-02-03
- **Final completion:** 2020-02-03
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Low patient recruitment
- **Last updated:** 2020-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02965443

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02965443, "Dapagliflozin + Saxagliptin in a Basal-bolus Insulin Treatment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02965443. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*